Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting
November 08 2018 - 7:30AM
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the
schedule of upcoming oral presentations and posters addressing
clinical and preclinical results with the company’s pan-caspase
inhibitor emricasan, or addressing preclinical results with the
company’s pan-caspase inhibitor IDN-7314, at The Liver Meeting®,
the annual meeting of the American Association for the Study of
Liver Diseases (AASLD) in San Francisco November 9-13, 2018.
- Poster #1226, “Multicenter, double-blind, randomized trial of
emricasan in subjects post liver transplantation (LT) with
recurrent hepatitis C virus (HCV) and liver fibrosis or cirrhosis
despite achieving sustained virologic response (SVR),” will be
displayed by Catherine Frenette, M.D., (Scripps Clinic, La Jolla,
CA) in the Liver Transplantation: Viral Hepatitis section on
Saturday, November 10, from 2:00 p.m. to 7:30 p.m. PT, in the
Moscone Center Poster Hall – Hall C.Presentation #251A,
highlighting selected content from poster #1226, will be delivered
by K. Rajinder Reddy, M.D., (University of Pennsylvania Medical
Center, Philadelphia, PA) in the Parallel 37: Liver
Transplantation: Alcohol and Hepatitis C session on Monday,
November 12, at 3:15 p.m. PT, in the Moscone Center Room
153/155.
- Presentation #25, “Intestinal dysbiosis augments liver disease
progression via NLRP3 in a murine model of primary sclerosing
cholangitis,” will be delivered by Kai M. Schneider (Department of
Internal Medicine III, University Hospital RWTH Aachen, Aachen,
Germany) in the Presidential Plenary Session on Translational
Science and Genomics on Tuesday, November 13, 9:00 a.m. PT., in the
Moscone Center General Session – Hall D.
- Poster #1344, “Molecular mechanisms underlying the effects of
emricasan in portal hypertension and chronic liver disease: the
hepato-sinusoidal cross-talk matters,” will be displayed by Jordi
Gracia-Sancho, Ph.D., (Idibaps Biomedical Research Institute,
Ciberehd, Barcelona, Spain; Hepatology, Inselspital, Bern,
Switzerland; and Barcelona Liver Services) in the Portal
Hypertension and Other Complications of Cirrhosis: Experimental
section on Saturday, November 10, from 2:00 p.m. to 7:30 p.m. PT,
in the Moscone Center Poster Hall – Hall C.
“With three ongoing ENCORE Phase 2b clinical trials evaluating
emricasan in patients with nonalcoholic steatohepatitis (NASH), all
with top-line results expected over the next nine months, we are
encouraged by the preclinical and clinical data being featured at
the AASLD meeting demonstrating the activity and effects of
pan-caspase inhibitors,” said Conatus co-founder, President and
Chief Executive Officer Steven J. Mento, Ph.D. “We thank our
principal investigators and our scientific collaborators for their
continued efforts to better understand and apply the multiple
mechanistic effects of caspase inhibitors on liver structure and
function, driving their disease-modifying potential. We are pleased
with the opportunity to share their latest findings at the AASLD
meeting, and we look forward to sharing results from the ENCORE
trials.”
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development of novel medicines
to treat liver disease. In collaboration with Novartis, Conatus is
developing its lead compound, emricasan, for the treatment of
patients with chronic liver disease. Emricasan is a first-in-class,
orally active pan-caspase inhibitor designed to reduce the activity
of enzymes that mediate inflammation and apoptosis. Conatus
believes that by reducing the activity of these enzymes, caspase
inhibitors have the potential to interrupt the progression of a
variety of diseases. For additional information, please visit
www.conatuspharma.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward-looking statements, including
statements regarding: the timeline for results from the
ENCORE trials; and caspase inhibitors’ potential to modify disease
and interrupt the progression of a variety of diseases. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative
of these terms or other similar expressions. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions,
including: the risk that the preclinical results may not be
predictive of future clinical trial results; Conatus’ ability to
successfully enroll patients in and complete its ongoing and
planned clinical trials; Conatus’ reliance on third parties to
conduct its clinical trials, including the enrollment of patients,
and manufacture its clinical drug supplies of emricasan; and those
risks described in the company’s prior press releases and in the
periodic reports it files with the Securities and Exchange
Commission. The events and circumstances reflected in the company’s
forward-looking statements may not be achieved or occur and actual
results could differ materially from those projected in the
forward-looking statements. Except as required by applicable law,
the company does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
CONTACT: Alan EngbringConatus
Pharmaceuticals Inc.(858) 376-2637aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2023 to Apr 2024